Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 16, 2014, 73 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $35.09 to $29,478,000.00.

Highlighted Stocks Traded by Insiders:

Biogen Idec (BIIB) - FREE Research Report

Schenk Lynn who is Director at Biogen Idec sold 1,000 shares at $297.48 on Jan. 16, 2014. Following this transaction, the Director owned 3,100 shares meaning that the stake was reduced by 24.39% with the 1,000-share transaction.

The shares most recently traded at $294.72, down $2.76, or 0.94% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 17,678
  • 24-Week # shares sold: 32,365

The average volume for Biogen Idec has been 1.3 million shares per day over the past 30 days. Biogen Idec has a market cap of $70.1 billion and is part of the health care sector and drugs industry. Shares are up 5.16% year-to-date as of the close of trading on Thursday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 41.7. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MedAssets (MDAS) - FREE Research Report

Garner Charles O who is Chief Financial Officer at MedAssets sold 15,207 shares at $20.83 on Jan. 16, 2014. Following this transaction, the Chief Financial Officer owned 5,069 shares meaning that the stake was reduced by 75% with the 15,207-share transaction.

The shares most recently traded at $21.77, up $0.94, or 4.3% since the insider transaction. Historical insider transactions for MedAssets go as follows:

  • 4-Week # shares sold: 13,000
  • 12-Week # shares sold: 225,000
  • 24-Week # shares sold: 296,305

The average volume for MedAssets has been 578,600 shares per day over the past 30 days. MedAssets has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 10.74% year-to-date as of the close of trading on Thursday.

MedAssets, Inc., a financial and performance improvement company, provides technology-enabled products and services for hospitals, health systems, and other ancillary healthcare providers in the United States. The company has a P/E ratio of 301.6. Currently there are 11 analysts that rate MedAssets a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDAS - FREE

TheStreet Quant Ratings rates MedAssets as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow. Get the full MedAssets Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Splunk (SPLK) - FREE Research Report

Neustaetter Thomas M who is Director at Splunk sold 1,500 shares at $75.72 on Jan. 16, 2014. Following this transaction, the Director owned 73,103 shares meaning that the stake was reduced by 2.01% with the 1,500-share transaction.

The shares most recently traded at $78.25, up $2.53, or 3.23% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 19,853
  • 12-Week # shares sold: 55,635
  • 24-Week # shares sold: 310,748

The average volume for Splunk has been 1.2 million shares per day over the past 30 days. Splunk has a market cap of $8.2 billion and is part of the technology sector and computer software & services industry. Shares are up 15.67% year-to-date as of the close of trading on Thursday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence. Currently there are 11 analysts that rate Splunk a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 2,000 shares at $22.90 on Jan. 16, 2014. Following this transaction, the SVP Software Development owned 835,517 shares meaning that the stake was reduced by 0.24% with the 2,000-share transaction.

The shares most recently traded at $22.95, up $0.05, or 0.23% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 53,000
  • 24-Week # shares sold: 110,000

The average volume for Interactive Brokers Group has been 556,000 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.2 billion and is part of the financial sector and financial services industry. Shares are down 5.71% year-to-date as of the close of trading on Thursday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.73%. The company has a P/E ratio of 26.8. Currently there are 2 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TD Ameritrade Holding Corporation (AMTD) - FREE Research Report

Moglia Joseph H who is Director at TD Ameritrade Holding Corporation sold 21,889 shares at $31.51 on Jan. 16, 2014. Following this transaction, the Director owned 747,055 shares meaning that the stake was reduced by 2.85% with the 21,889-share transaction.

The shares most recently traded at $32.43, up $0.92, or 2.84% since the insider transaction. Historical insider transactions for TD Ameritrade Holding Corporation go as follows:

  • 4-Week # shares sold: 88,540
  • 12-Week # shares sold: 5.7 million
  • 24-Week # shares sold: 5.7 million

The average volume for TD Ameritrade Holding Corporation has been 2.0 million shares per day over the past 30 days. TD Ameritrade Holding Corporation has a market cap of $17.5 billion and is part of the financial sector and financial services industry. Shares are up 5.74% year-to-date as of the close of trading on Thursday.

TD Ameritrade Holding Corporation provides securities brokerage services and technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. The stock currently has a dividend yield of 1.51%. The company has a P/E ratio of 26.1. Currently there are 7 analysts that rate TD Ameritrade Holding Corporation a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMTD - FREE

TheStreet Quant Ratings rates TD Ameritrade Holding Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full TD Ameritrade Holding Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null